Arctic Bioscience — Report Publication Announcement 2021

Aug 20, 2021

Arctic Bioscience AS: Invitation to Presentation of H1 2021 Results

Arctic Bioscience AS: Invitation to Presentation of H1 2021 Results

Arctic Bioscience AS will publish its financial results for the first half of

2021 on

Thursday August 26, 2021, at 07:00 CEST. The company will host a webcast

presentation of the results the same day at 08:30 CEST.

Arctic Bioscience AS H1 2021 webcast presentation:

Date: Thursday August 26, 2021

Time: 08:30 a.m. CEST

Format: Webcast and Q&A

Language: English

Link: https://streams.eventcdn.net/arcticbioscienceas/financial-results-first

-half-2021/register

The H1 2021 report and presentation will be made available at www.arctic

-bioscience.com

and on the Euronext Growth company

page (https://live.euronext.com/nb/product/equities/NO0010859580-MERK).

This information is subject to the disclosure requirements in EU Market Abuse

Regulations (MAR) 596/2014 article 19 number 3 and the Norwegian Securities

Trading Act § 5-12.

For further information, please contact:

Danielle Glenn, CFO

Mobile: +47 909 98 201

Email: danielle@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing pharmaceutical and

nutraceutical products based on the unique properties of herring roe oil,

composed of complex bioactive marine compounds, including lipids essential to

maintaining cell membranes. The nutraceutical products contain lipids which

contribute to the normal functioning of brain, heart and vision.

The company is developing a novel drug candidate (HRO350) for mild-to-moderate

psoriasis, a large global patient population where there is substantial need for

effective, convenient and cost-effective new medicines with beneficial safety

profiles. Nutraceuticals from Arctic Bioscience are sold worldwide as bulk

ingredients to other companies making dietary supplements (B2B) and as finished

goods under the ROMEGAT brand (B2C), with significant expansion potential all

channels and regions.

To support its long-term growth strategy, Arctic Bioscience is planning a state

-of-the-art manufacturing facility in Ørsta. Easy access to the raw material and

proprietary production processes will increase control of the value chain,

improve margins and enable large-scale, high-quality manufacturing.

Arctic Bioscience is led by a highly competent team with significant expertise

developing marine oils and extensive experience from some of the world's leading

pharmaceutical, technology and financial services companies.